TD Cowen lifts Axsome stock target to $155, maintains Buy rating
TD Cowen, a well-established research firm, increased its price target on Axsome Therapeutics (NASDAQ:AXSM) shares, raising the figure to $155 from the previous target of $125. The firm reaffirmed its ...
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Nurix Therapeutics (NRIX) and Merit Medical Systems (MMSI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research ...